Troendle sells Medpace stock. UBS sets a USD 673 target.

Published on 10/07/2026 at 05:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 707.33 million, up 17.20 percent year over year. The average target for Medpace stock is USD 602.27.

MEDP, US58506Q1094, Illustration mit AI erstellt.

August Troendle sold 48,667 Medpace shares in transactions dated September 29 and September 30, 2026, while UBS set a USD 673.00 target after a previous USD 405.00 target. Investing.com reported the transactions on October 2, 2026, and MarketBeat identified the UBS target change in its October 1, 2026 report.

Insider sale meets target reset

The sale involved less than 1.00 percent of Troendle's reported holdings, making the transaction a limited ownership signal rather than a broad change in management exposure. UBS's move is more consequential for valuation: the USD 673.00 target stands 66.17 percent above the previous USD 405.00 target.

MarketBeat also reported that UBS moved its rating to Neutral from Sell. The same report listed a broader Hold consensus, with three Buy ratings and ten Holds and an average target of USD 602.27.

Second-quarter growth sets the bar

Medpace generated USD 707.33 million of revenue in the second quarter of 2026, up 17.20 percent from USD 603.30 million in the second quarter of 2025. MarketBeat reported diluted earnings per share of USD 4.25 against a USD 3.98 consensus estimate for the period.

The USD 0.27 earnings-per-share gap and the 17.20 percent revenue increase explain why the latest analyst debate centers on valuation and future growth rather than the second-quarter operating result. Medpace's full-year 2026 earnings-per-share guidance stands at USD 17.25 to USD 17.95, according to the same MarketBeat report.

Nasdaq valuation stays elevated

Medpace was last at USD 602.90 on Nasdaq on October 6, 2026 at 4:00 p.m. ET. That level was 11.06 percent below the USD 677.90 52-week high and left the company with a USD 16.8 billion market capitalization.

The valuation leaves a clear tension in the numbers: the latest quarter delivered double-digit growth, while the UBS target sits USD 70.10 above the October 6 Nasdaq level. The next test is the company's ability to sustain bookings and revenue growth into the second half of 2026.

Next results date is October 21

Business Wire reported that Medpace will publish third-quarter 2026 financial results after the market close on October 21, 2026, followed by a conference call on October 22, 2026 at 9:00 a.m. ET. The prior close at Lang & Schwarz was EUR 535.50 on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Medpace stock.